Abstract
The discovery and development of induced pluripotent stem cells (iPSCs) opened a novel venue for disease modeling, drug discovery, and personalized medicine. Additionally, iPSCs have been utilized for a wide variety of research and clinical applications without immunological and ethical concerns that encounter embryonic stem cells. Adoptive T cell immunotherapy is a form of cellular immunotherapy that involves transfusion of functional T cells. However, this approach requires T cell expansion and the process causes T cell exhaustion. As a result, highly expanded T cells have not proven to be particularly effective for treatments. This exhaustion issue could be overcome due to rejuvenation of T cells by reprogramming to pluripotency and redifferentiation to T cells. This is a potential therapeutic strategy for combating various types of cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv324. https://doi.org/10.1126/scitranslmed.aad7118
Naidoo J et al (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4:383–389. https://doi.org/10.1158/2326-6066.CIR-15-0123
Morello A, Sadelain M, Adusumilli PS (2016) Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 6:133–146. https://doi.org/10.1158/2159-8290.CD-15-0583
Adusumilli PS et al (2014) Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6:261ra151. https://doi.org/10.1126/scitranslmed.3010162
Wu R et al (2012) Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18:160–175. https://doi.org/10.1097/PPO.0b013e31824d4465
Tran E et al (2016) T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375:2255–2262. https://doi.org/10.1056/NEJMoa1609279
Ghoneim HE, Zamora AE, Thomas PG, Youngblood BA (2016) Cell-intrinsic barriers of T cell-based immunotherapy. Trends Mol Med 22:1000–1011. https://doi.org/10.1016/j.molmed.2016.10.002
Nishimura T et al (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12:114–126. https://doi.org/10.1016/j.stem.2012.11.002
Vizcardo R et al (2013) Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12:31–36. https://doi.org/10.1016/j.stem.2012.12.006
Acknowledgments
The study was supported by the fellowship to T.N. from Japanese Society for the Promotion of Science (JSPS) and The Quest Award to H.N. from California Institute for Regenerative Medicine (CIRM).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Nishimura, T., Murmann, Y., Nakauchi, H. (2019). Human iPSC Generation from Antigen-Specific T Cells. In: Kaneko, S. (eds) In Vitro Differentiation of T-Cells. Methods in Molecular Biology, vol 2048. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9728-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9728-2_5
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9727-5
Online ISBN: 978-1-4939-9728-2
eBook Packages: Springer Protocols